The European Medicines Agency has launched a review into the safety of Type 2 diabetes medicines called SGLT2 inhibitors. The European Medicines Agency
The review was requested by the European Commission following over a hundred cases of diabetic ketoacidosis (DKA) in patients treated with canagliflozin, dapagliflozin and empagliflozin, which are medicines known as SGLT2 inhibitors. reviewEuropean Commission
Patients who use these drugs should consult their doctor if they have any of the symptoms of DKA, which include excessive thirst, unusual fatigue, and confusion, or if their blood glucose levels go high.
However, it is important that people with diabetes do not stop taking their prescribed medication without first consulting their doctor.
While the investigation is ongoing, healthcare professionals who are treating patients with SGLT2 inhibitors are advised to do the following:
- Inform patients of the symptoms and signs of DKA (e.g. nausea, vomiting, abdominalpain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness)
- Test for raised ketones in patients with symptoms of diabetic ketoacidosis (DKA) even if plasma glucose levels are near normal; omitting this test could delay diagnosis.If you suspect DKA, stop SGLT2 inhibitor treatment.
- If DKA is confirmed, take appropriate measures to correct the DKA and to monitor glucose levels.Be aware that SGLT2 inhibitors are not approved for treatment of Type 1 diabetes
- YELLOW Card
Simon O’Neill, Diabetes UK Director of Health Intelligence, said: “The number of reported cases of diabetic ketoacidosis in patients treated with SGLT2 inhibitors is very small. However, it is important that patients consult their doctor if they feel unwell and their blood glucose levels go high. Patient safety is of paramount importance and we await the results of the European Medicines Agency investigation into the long-term safety of these drugs with interest.”